Covered recipient · General Payments record
BRIAN ALEXANDER TONG
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
General Payments · PY2020–2024
$1,828.53
- Reported across 78 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $337.38 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| UCB, Inc. | $133.56 | 5 |
| Neurelis, Inc. | $34.74 | 2 |
| Teva Pharmaceuticals USA, Inc. | $26.29 | 1 |
| Marinus Pharmaceuticals, Inc. | $23.98 | 1 |
| Merz Pharmaceuticals, LLC | $23.07 | 1 |
| Otsuka America Pharmaceutical, Inc. | $23.00 | 1 |
| Renalytix AI, Inc. | $21.51 | 1 |
| ViiV Healthcare Company | $19.25 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $18.43 | 1 |
| LivaNova USA, Inc. | $13.55 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| LivaNova USA, Inc. | $13.55 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1152799961 | CMS |
| Marinus Pharmaceuticals, Inc. | $23.98 | 06/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141324522 | CMS |
| Merz Pharmaceuticals, LLC | $23.07 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137947386 | CMS |
| Neurelis, Inc. | $14.84 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145657168 | CMS |
| Neurelis, Inc. | $19.90 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145657170 | CMS |
| Otsuka America Pharmaceutical, Inc. | $23.00 | 01/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118994750 | CMS |
| Renalytix AI, Inc. | $21.51 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116760186 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $18.43 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137688480 | CMS |
| Teva Pharmaceuticals USA, Inc. | $26.29 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151737707 | CMS |
| UCB, Inc. | $25.68 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143458339 | CMS |
| UCB, Inc. | $19.70 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143458344 | CMS |
| UCB, Inc. | $29.23 | 04/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143458348 | CMS |
| UCB, Inc. | $30.49 | 05/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143458352 | CMS |
| UCB, Inc. | $28.46 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143458356 | CMS |
| ViiV Healthcare Company | $19.25 | 08/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1112735523 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2020, 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.